Insights from studying human sleep disorders

Nature

Volumn 437, Issue 7063, 2005, Pages 1279-1285

  Mahowald, Mark W ^a   Schenck, Carlos H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DIAGNOSIS; EYE MOVEMENTS; MEDICAL PROBLEMS; NEUROLOGY;

BRAIN PHENOMENA; RAPID EYE MOVEMENT (REM); SLEEP DISORDERS; THERAPEUTICS;

SLEEP RESEARCH;

HLA DQ1 ANTIGEN; HLA DR15 ANTIGEN; HLA DR2 ANTIGEN; OREXIN; SEROTONIN UPTAKE INHIBITOR;

SLEEP;

AROUSAL; BRAIN; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM SLEEP DISORDER; DEPRESSION; ELECTROENCEPHALOGRAM; GENE; HUMAN; HYPERSOMNIA; INSOMNIA; MEDICAL CARE; NARCOLEPSY; PARASOMNIA; PRIORITY JOURNAL; REM SLEEP; REM SLEEP DEPRIVATION; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WALKING; SLOW WAVE SLEEP; SOCIOECONOMICS; WAKEFULNESS;

ANIMALIA;

EID: 27644447357     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04287     Document Type: Review

References (77)

1. National Commission on Sleep Disorders Research. Report of the National Commission on Sleep Disorders Research (Research DHHS Pub. No. 92. Supplier of Documents, U. S. Government Printing Office, Washington, DC, 1992).
2. Caples, S. M., Garni, A. S. & Somers, V. K. Obstructive sleep apnea. Ann. Intern. Med. 142, 187-197 (2005).
3. Guillemiault, C. & Framherz, S. in Principles and Practice of Sleep Medicine (eds Kryger, M. H., Roth, T. & Dement, W. C.) 780-790 (Elsevier Saunders, Philadelphia, 2005).
4. Nobili, L. et al. Ultradian aspects of sleep in narcolepsy. Neurophysiol. Clin. 26, 51-59 (1996).
5. Bassetti, C. & Aldrich, M. S. Narcolepsy. Neurologic Clinics 14, 545-571 (1996).
6. Mignot, E. Genetic and familial aspects of narcolepsy. Neurology 50 (suppl. 1), S16-S22 (1998).
7. Taheri, S., Zeitzer, J. M. & Mignot, E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25, 283-313 (2002).
8. Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553-1562 (2002).
9. Johns, J., Wu, M.-F. & Siegel, J. M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res. Online 3, 23-28 (2000).
10. Bonnet, M. H. & Arand, D. L. Activity, arousal, and the MSLT in patients with insomnia. Sleep 23, 205-212 (2000).
11. Stepanski, E., Zorick, F., Roehrs, T., Young, D. & Roth, T. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 11, 54-60 (1998).
12. Vgontzas, A. N. et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J. Endocrinol. Metab. 86, 3787-3794 (2001).
13. Perlis, M. L., Merica, H., Smith, M. T. & Giles, D. E. Beta EEG activity and insomnia. Sleep Med. Rev. 5, 365-376 (2001).
14. Smith, M. T. et al. Neuroimaging of NREM sleep in primary insomnia: a Tc-99-HMPAO single photon emission computed tomographic study. Sleep 25, 325-335 (2002).
15. Lasagna, L. Over-the-counter hypnotics and chronic insomnia in tine elderly. J. Clin. Psychopharmacol. 15, 383-386 (1995).
16. Mendelson, W. B. et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med. Rev. 8, 7-17 (2004).
17. Schenck, C. H. & Mahowald, M. W. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am. J. Med. 100, 333-337 (1996).
18. Hajak, G., Bandelow, B., Zulley, J. & Pittrow, D. 'As needed' pharmacotherapy combined with stimulus control treatment in chronic insomnia - assessment of a novel interventional strategy in a primary care setting. Ann. Clin. Psychiatry 14, 1-7 (2002).
19. Morin, C. M., Bastien, C. H., Brink, D. & Brown, T. R. Adverse effects of temazepam in older adults with chronic insomnia. Hum. Pschyopharmacol. Clin. Exper. 18, 75-82 (2003).
20. Dawson, D. & van den Heuvel, C. J. Integrating the actions of melatonin on human physiology. Ann. Med. 30, 95-102 (1998).
21. Phillips, B. et al. Epidemiology of restless legs symptoms in adults. Arch. Intern. Med. 160, 2137-2141 (2000).
22. Trenkwalder, C. et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov. Dis. 14, 102-110 (1999).
23. Winkelman, J. et al. 'Anxietas Tibiarum'. Depression and anxiety disorders in patients with restless legs syndrome. J. Neurol. 252, 67-71 (2005).
24. Desautels, A. et al. Restless legs syndrome. Confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch. Neurol. 62, 591-596 (2005).
25. Allen, R. P. & Earley, C. J. Restless legs syndrome: a review of clinical and pathophysiologic features. J. Clin. Neurophysiol. 18, 128-147 (2001).
26. Bucher, S. F., Seelos, K. C., Oertel, W. H., Reiser, M. & Trenkwalder, C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann. Neurol. 41, 639-645 (1997).
27. Turjanski, N., Lees, A. J. & Brooks, D. J. Striatal dopaminergic function in restless legs syndrome. Neurology 52, 932-937 (1999).
28. Tergau, F., Wischer, S. & Paulus, W. Motor system excitability in patients with restless legs syndrome. Neurology 52, 1060-1063 (1999).
29. Stiasny-Kolster, K., Magerl, W., Oertel, W. H., Moller, J. C. & Treede, R.-D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127, 773-782 (2004).
30. von Spiczak, S. et al. The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain 128, 906-917 (2005).
31. Moore-Ede, M. C., Sulzman, F. M. & Fuller, C. A. The Clocks That Time Us: Physiology of the Circadian Timing System (Harvard Univ. Press, Cambridge, MA, 1982).
32. Sack, R. L., Lewy, A. J., Blood, M. L., Keith, L. D. & Nakagawa, H. Circadian rhythm abnormalities in totally blind people; incidence and clinical significance. J. Clin. Endocrinol. Metab. 75, 127-134 (1992).
33. Sack, R. L., Lewy, A. J. & Hughes, R. J. Guidelines for prescribing melatonin for sleep and circadian rhythm disorders. Ann. Med. 30, 115-121 (1998).
34. Czeisler, C. A., Richardson, G. S. & Coleman, R. M. Chronotherapy: resetting the circadian clocks of patients with delayed sleep phase insomnia. Sleep 4, 1-21 (1981).
35. Reid, K. J. & Zee, P. C. in Principles and Practice of Sleep Medicine (eds Kryger, M. H., Roth, T. & Dement, W. C.) 691-701 (Elsevier Saunders, Philadelphia, 2005).
36. Yamadera, H., Takahashi, K. & Okawa, M. A multicenter study of sleep-wake rhythm disorders: clinical features of sleep-wake rhythm disorders. Psychiatr. Clin. Neurosci. 50, 195-201 (1996).
37. Xu, W. et al. Functional consequences of a CKI-delta mutation causing familial advanced sleep phase syndrome. Nature 434, 640-644 (2005).
38. Toh, K. L. et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 291, 1040-1043 (2001).
39. Archer, S. N. et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 26, 413-415 (2003).
40. Dagan, Y., Yovel, I., Hallis, D., Eisenstein, M. & Raichik, I. Evaluating the role of melatonin in the long-term treatment of delayed sleep phase syndrome (DSPS). Cnronobiol. Inter. 15, 181-190 (1998).
41. Mahowald, M. W. & Schenck, C. H. Evolving concepts of human state dissociation. Arch. Ital. Biol. 139, 269-300 (2001).
42. Mahowald, M. W. & Schenck, C. H. in Principles and Practice of Sleep Medicine (eds. Kryger, M. H., Roth, T. & Dement, W. C.) 786-795 (W. B. Saunders, Philadelphia, 2000).
43. Fisher, C., Kahn, E., Edwards, A. & Davis, D. M. A psychophysiological study of nightmares and night terrors. I. Physiological aspects of the stage 4 night terror. J. Nerv. Ment. Dis. 157, 75-98 (1973).
44. Fisher, C., Kahn, E., Edwards, A., Davis, D. M. & Fine, J. A psychophysiological study of nightmares and night terrors. III. Mental content and recall of stage 4 night terrors. J. Nerv. Ment. Dis. 158, 174-188 (1974).
45. Schenck, C. H., Hurwitz, T. D., Bundlie, S. R. & Mahowald, M. W. Sleep-related injury in 100 adult patients: a polysomnographic and clinical report. Am. J. Psychiatr. 146, 1166-1173 (1989).
46. Guilleminault, C., Moscovitch, A. & Leger, D. Forensic sleep medicine: nocturnal wandering and violence. Sleep 18, 740-748 (1995).
47. Llorente, M. D., Currier, M. B., Norman, S. & Mellman, T. A. Night terrors in adults: phenomenology and relationship to psychopathology. J. Clin. Psychiatr. 53, 392-394 (1992).
48. Shapiro, C. M., Trajanovic, N. N. & Fedoroff, J. P. Sexsomnia - a new parasomnia? Can. J. Psychiatr. 48, 311-317 (2003).
49. Winkelman, J. W., Herzog, D. B. & Fava, M. The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations. Psychol. Med. 29, 1461-1466 (1999).
50. Schenck, C. H. & Mahowald, M. W. Review of nocturnal sleep-related eating disorders. Int. J. Eat Dis. 15, 343-356 (1994).
51. Rosenfeld, D. S. & Elhajjar, A. J. Sleepsex: a variant of sleepwalking. Arch. Sex. Behav. 27, 269-278 (1998).
52. Rosen, G., Mahowald, M. W. & Ferber, R. in Principles and Practice of Sleep Medicine in the Child (eds Ferber, R. & Kryger, M.) 99-106 (W. B. Saunders, Philadelphia, 1995).
53. Nino-Murcia, G. & Dement, W. C. in Psychopharmacology: the Third Generation of Progress (ed. Meltzer, H. Y.) 873-879 (Raven, New York, 1987).
54. Ohayon, M., Guilleminault, C. & Priest, R. G. Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders. J. Clin. Psychiatr. 60, 268-276 (1999).
55. Klackenberg, G. Somnambulism in childhood - prevalence, course and behavior correlates. A prospective longitudinal study (6-16 years). Acta Paediatr. Scan. 71, 495-499 (1982).
56. Kahn, E., Fisher, C. & Edwards, A. in The Mind in Sleep. Psychology and Psychophysiology (eds Ellman, S. D. & Antrobus, J. S.) 437-447 (John Wiley & Sons, New York, 1991).
57. Mahowald, M. W. & Schenck, C. H. in Principles and Practice of Sleep Medicine (eds Kryger, M. H., Roth, T. & Dement, W. C.) 960-968 (Elsevier/Saunders, Philadelphia, 2005).
58. Mahowald, M. W. & Cramer-Bornemann, M. A. in Principles and Practice of Sleep Medicine (eds Kryger, M. H., Roth, T. & Dement, W. C.) 889-896 (Elsevier/Saunders, Philadelphia, 2005).
59. Schenck, C. H. in Encyclopedia of the Neurological Sciences (eds Aminoff, M. J. & Daroff, R. B.) 146-149 (Academic, San Diego, 2003).
60. Mahowald, M. W. & Schenck, C. H. in Principles and Practice of Sleep Medicine (eds. Kryger, M. H., Roth, T. & Dement, W. C.) 897-916 (Elsevier/Saunders, Philadelphia, 2005).
61. Boeve, B. F. et al. Synuceinopathy pathology often underlies REM sleep behavior disorder and dementia or parkinsonism. Neurology 61, 40-45 (2003).
62. Eisensehr, I. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. Comparison with Parkinson's disease and controls. Brain 123, 1155-1160 (2000).
63. Eisensehr, I. et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 26, 507-512 (2003).
64. Albin, R. L. et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55, 1410-1412 (2000).
65. Shirakawa, S.-I. et al. Study of image findings in rapid eye movement sleep behavioral disorder. Psychiatr. Clin. Neurosci. 56, 291-292 (2002).
66. Fantini, M. L. et al. Slowing of electroencephalogram in rapid eye movement sleep behavior disorder. Ann. Neurol. 53, 774-780 (2003).
67. Miyamoto, M. et al. Brainstem function in rapid eye movement sleep behavior disorder: the evaluation of brainstem function by proton MR spectroscopy (1H-MRS). Psychiatr. Clin. Neurosci. 54, 350-351 (2000).
68. Gilman, S. et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 61, 29-34 (2003).
69. Schenck, C. H. & Mahowald, M. W. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann. Neurol. 32, 3-10 (1992).
70. Schenck, C. H. & Mahowald, M. W. Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleveland Clin. J. Med. 57 (Suppl.), S9-S23 (1990).
71. Petersen, A. et al. Orexin loss in Huntington's disease. Hum. Mol. Genet. 14, 39-47 (2005).
72. Morton, A. J. et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25, 1573-163 (2005).
73. Wisor, J. P. et al. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131, 375-385 (2005).
74. Dauvilliers, Y., Maret, S. & Tafti, M. Genetics of normal and pathological sleep. Sleep Med. Rev. 9, 91-100 (2005).
75. Huber, R. et al. Sleep homeostasis in Drosophila melanogaster. Sleep 27, 628-639 (2004).
76. Hendricks, J. C. & Sehgal, A. Why a fly? Using Drosophila to understand the genetics of circadian rhythms and sleep. Sleep 27, 334-342 (2004).
77. Cirelli, C. et al. Reduced sleep in Drosophila Shaker mutants. Nature 434, 1087-1092 (2005).